MBX Biosciences Inc’s recently made public that its Director Pescovitz Ora H. acquired Company’s shares for reported $45312.0 on Apr 08 ’25. In the deal valued at $5.89 per share,7,693 shares were bought. As a result of this transaction, Pescovitz Ora H. now holds 24,329 shares worth roughly $0.27 million.
Then, GORDON CARL L bought 143,170 shares, generating $1,551,963 in total proceeds. Upon buying the shares at $10.84, the Director now owns 3,255,000 shares.
Before that, GORDON CARL L bought 47,502 shares. MBX Biosciences Inc shares valued at $468,793 were divested by the Director at a price of $9.87 per share. As a result of the transaction, GORDON CARL L now holds 3,205,930 shares, worth roughly $35.43 million.
Citizens JMP initiated its MBX Biosciences Inc [MBX] rating to a Mkt outperform in a research note published on April 10, 2025; the price target was $38. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. JP Morgan began covering MBX with “an Overweight” recommendation on October 08, 2024. Jefferies started covering the stock on October 08, 2024. It rated MBX as “a Buy”.
Price Performance Review of MBX
On Tuesday, MBX Biosciences Inc [NASDAQ:MBX] saw its stock jump 13.57% to $11.05. Over the last five days, the stock has gained 5.24%. Nevertheless, the stocks have fallen -40.04% over the past one year.
Levels Of Support And Resistance For MBX Stock
The 24-hour chart illustrates a support level at 10.10, which if violated will result in even more drops to 9.15. On the upside, there is a resistance level at 11.62. A further resistance level may holdings at 12.19.
How much short interest is there in MBX Biosciences Inc?
A steep rise in short interest was recorded in MBX Biosciences Inc stocks on 2025-05-30, dropping by -0.64 million shares to a total of 4.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 5.38 million shares. There was a decline of -13.41%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 08, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $44 price target.
